12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Enzalutamide: Phase II started

Medivation began an open-label, international Phase II trial to evaluate 160 mg oral enzalutamide once daily in about 80 patients. Enzalutamide is approved as Xtandi in the U.S.,...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >